For An Ultra-High-Priced Drug, Alnylam Brings A New Idea
Executive SummaryThe company will launch Givlaari with a novel prevalence-based adjustment feature for payers, which will trigger higher rebates if the number of diagnosed patients is higher than expected.
You may also be interested in...
The company expects to complete a rolling NDA submission for its second RNAi therapeutic in mid-2019, and sees an opportunity to target severe and more moderate patients with acute hepatic porphyria.
The company is looking at deals in the $2bn to $5bn range, CEO Paul Hudson told investors, but premiums for assets are high and Sanofi is looking at earlier-stage opportunities as a result.